 1. Comparison the pre- and post-treatment prevalence of the t14:18 translocation, in peripheral blood and bone marrow, of patients treated with either IFRT alone or IFRT plus chemotherapy. This translocation is potentially a marker for minimal residual disease and eradication of the marker from blood cells may have prognostic implications. The clinical value of molecular remission as an early predictor of freedom from progression FFP and survival will be assessed. 